340 related articles for article (PubMed ID: 35876967)
1. Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5.
Liu CH; Kao JH
Hepatol Int; 2022 Oct; 16(5):1001-1019. PubMed ID: 35876967
[TBL] [Abstract][Full Text] [Related]
2. Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease.
Fabrizi F; Tripodi F; Cerutti R; Nardelli L; Alfieri CM; Donato MF; Castellano G
Viruses; 2022 Nov; 14(11):. PubMed ID: 36423179
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease.
Ridruejo E; Garcia-Agudo R; Mendizabal M; Aoufi-Rabih S; Dixit V; Silva M; Fabrizi F
Nefrologia (Engl Ed); 2020; 40(1):46-52. PubMed ID: 31229261
[TBL] [Abstract][Full Text] [Related]
4. Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease.
Ryu JE; Song MJ; Kim SH; Kwon JH; Yoo SH; Nam SW; Nam HC; Kim HY; Kim CW; Yang H; Bae SH; Song DS; Chang UI; Yang JM; Lee SW; Lee HL; Lee SK; Sung PS; Jang JW; Choi JY; Yoon SK
Korean J Intern Med; 2022 Sep; 37(5):958-968. PubMed ID: 35981893
[TBL] [Abstract][Full Text] [Related]
5. Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.
Chahine EB; Kelley D; Childs-Kean LM
Ann Pharmacother; 2018 Apr; 52(4):352-363. PubMed ID: 29115151
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials.
Heo J; Kim YJ; Lee JW; Kim JH; Lim YS; Han KH; Jeong SH; Cho M; Yoon KT; Bae SH; Crown ED; Fredrick LM; Alami NN; Asatryan A; Kim DH; Paik SW; Lee YJ
Gut Liver; 2021 Nov; 15(6):895-903. PubMed ID: 34053916
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
Borgia SM; Dearden J; Yoshida EM; Shafran SD; Brown A; Ben-Ari Z; Cramp ME; Cooper C; Foxton M; Rodriguez CF; Esteban R; Hyland R; Lu S; Kirby BJ; Meng A; Markova S; Dvory-Sobol H; Osinusi AO; Bruck R; Ampuero J; Ryder SD; Agarwal K; Fox R; Shaw D; Haider S; Willems B; Lurie Y; Calleja JL; Gane EJ
J Hepatol; 2019 Oct; 71(4):660-665. PubMed ID: 31195062
[TBL] [Abstract][Full Text] [Related]
9. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.
Chen CT; Lu MY; Hsieh MH; Tsai PC; Hsieh TY; Yeh ML; Huang CI; Tsai YS; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Huang CF; Huang JF; Dai CY; Chuang WL; Shih YL; Yu ML
World J Gastroenterol; 2022 Jan; 28(2):263-274. PubMed ID: 35110949
[TBL] [Abstract][Full Text] [Related]
10. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
[TBL] [Abstract][Full Text] [Related]
11. Long-term durability of sustained virologic response for hepatitis C virus infection in solid organ transplant recipients receiving direct-acting antivirals.
Liu CH; Chen YS; Tsai MK; Wang SS; Lee CY; Tsao CI; Liu CJ; Su TH; Tseng TC; Huang SC; Wu JH; Chen PJ; Kao JH
J Formos Med Assoc; 2023 Aug; 122(8):800-804. PubMed ID: 36941177
[TBL] [Abstract][Full Text] [Related]
12. Antiviral Treatment Failures After Transplantation of Organs From Donors With Hepatitis C Infection: A Report of 4 Cases.
Steinbrink JM; Narayanasamy S; Wolfe CR; Maziarz E; Byrns J; Kiser JJ; Naggie S
Am J Kidney Dis; 2023 Sep; 82(3):368-372. PubMed ID: 36740039
[TBL] [Abstract][Full Text] [Related]
13. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals.
Liu CH; Lee MH; Lin JW; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
J Hepatol; 2020 May; 72(5):839-846. PubMed ID: 31790766
[TBL] [Abstract][Full Text] [Related]
14. Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals.
Pisaturo M; Starace M; Minichini C; De Pascalis S; Occhiello L; Fraia AD; Messina V; Sangiovanni V; Claar E; Coppola N;
Int J Antimicrob Agents; 2020 Sep; 56(3):106067. PubMed ID: 32599227
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
Goel A; Chen Q; Chhatwal J; Aggarwal R
J Gastroenterol Hepatol; 2018 Dec; 33(12):2029-2036. PubMed ID: 29864213
[TBL] [Abstract][Full Text] [Related]
16. Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease.
Ogawa E; Furusyo N; Azuma K; Nakamuta M; Nomura H; Dohmen K; Satoh T; Kawano A; Koyanagi T; Ooho A; Takahashi K; Kato M; Shimoda S; Kajiwara E; Hayashi J;
Antiviral Res; 2018 Nov; 159():143-152. PubMed ID: 30300717
[TBL] [Abstract][Full Text] [Related]
17. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.
Sezaki H; Suzuki F; Hosaka T; Fujiyama S; Kawamura Y; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Gastroenterol; 2019 Oct; 54(10):916-927. PubMed ID: 30903385
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of pan-genotypic therapies for the treatment of patients with hepatitis C virus infection in Bulgaria.
Djambazov S; Slavchev G; Encheva M; Mitova R; Vekov T
J Comp Eff Res; 2019 May; 8(7):455-459. PubMed ID: 30920311
[TBL] [Abstract][Full Text] [Related]
19. Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections.
Sun HY; Cheng CY; Lin CY; Yang CJ; Lee NY; Liou BH; Tang HJ; Liu YM; Lee CY; Chen TC; Huang YC; Lee YT; Tsai MJ; Lu PL; Tsai HC; Wang NC; Hung TC; Cheng SH; Hung CC
World J Gastroenterol; 2022 Mar; 28(11):1172-1183. PubMed ID: 35431505
[TBL] [Abstract][Full Text] [Related]
20. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
Kwo PY; Poordad F; Asatryan A; Wang S; Wyles DL; Hassanein T; Felizarta F; Sulkowski MS; Gane E; Maliakkal B; Overcash JS; Gordon SC; Muir AJ; Aguilar H; Agarwal K; Dore GJ; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
J Hepatol; 2017 Aug; 67(2):263-271. PubMed ID: 28412293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
